Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis

Reproductive Sciences

Volumn 22, Issue 9, 2015, Pages 1171-1180

  Leconte, Mahaut ^a,b   Santulli, Pietro ^a,b   Chouzenoux, Sandrine ^a   Marcellin, Louis ^a,b   Cerles, Olivier ^a   Chapron, Charles ^a,b   Dousset, Bertrand ^a,b   Batteux, Frédéric ^a,b  

^a INSTITUT COCHIN   (France)

^b AP HP ^*  (France)

Author keywords

endometriosis; MAPK; RAF kinase; sorafenib; VEGFR 2

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; SORAFENIB; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; CARBANILAMIDE DERIVATIVE; KDR PROTEIN, HUMAN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIOSIS; ENDOMETRIUM BIOPSY; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIMARY CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STROMA CELL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; CELL CULTURE; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENDOMETRIUM; ENZYMOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME FACTOR; TRANSPLANTATION; VASCULARIZATION; XENOGRAFT;

ADULT; ANIMALS; APOPTOSIS; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIOSIS; ENDOMETRIUM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HETEROGRAFTS; HUMANS; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STROMAL CELLS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84939133110     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719115592708     Document Type: Article

References (50)

1. de Ziegler D, Borghese B, Chapron C,. Endometriosis and infertility: pathophysiology and management. Lancet. 2010; 376 (9742): 730-738.
2. Giudice LC, Kao LC,. Endometriosis. Lancet. 2004; 364 (9447): 1789-1799.
3. Berkley KJ, Rapkin AJ, Papka RE,. The pains of endometriosis. Science. 2005; 308 (5728): 1587-1589.
4. Sampson JA,. Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927; 14: 442-469.
5. Chapron C, Chopin N, Borghese B,. Deeply infiltrating endometriosis: pathogenetic implications of the anatomical distribution. Hum Reprod. 2006; 21 (7): 1839-1845.
6. Bulun SE,. Endometriosis. N Engl J Med. 2009; 360 (3): 268-279.
7. Hsu CY, Hsieh TH, Tsai CF, et al. miRNA-199a-5p regulates VEGFA in endometrial mesenchymal stem cells and contributes to the pathogenesis of endometriosis. J Pathol. 2014; 232 (3): 330-343.
8. Laschke MW, Giebels C, Menger MD,. Vasculogenesis: a new piece of the endometriosis puzzle. Hum Reprod Update. 2011; 17 (5): 628-636.
9. Laschke MW, Menger MD,. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Upd. 2007; 13 (4): 331-342.
10. Laschke MW, Menger MD,. Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update. 2012; 18 (6): 682-702.
11. Anaf V, Simon P, El Nakadi I,. Relationship between endometriotic foci and nerves in rectovaginal endometriotic nodules. Hum Reprod. 2000; 15 (8): 1744-1750.
12. Yuge A, Nasu K, Matsumoto H, Nishida M, Narahara H,. Collagen gel contractility is enhanced in human endometriotic stromal cells: a possible mechanism underlying the pathogenesis of endometriosis-associated fibrosis. Hum Reprod. 2007; 22 (4): 938-944.
13. Itoga T, Matsumoto T, Takeuchi H,. Fibrosis and smooth muscle metaplasia in rectovaginal endometriosis. Pathol Int. 2003; 53 (6): 371-375.
14. Santulli P, Marcellin L, Noel JC,. Sphingosine pathway deregulation in endometriotic tissues. Fertil Steril. 2012; 97 (4): 904-911.
15. Santulli P, Borghese B, Noel JC,. Hormonal Therapy Deregulates Prostaglandin-Endoperoxidase Synthase 2 (PTGS2) expression in endometriotic tissues. J Clin Endocrinol Metab. 2014; 99 (3): 881-890.
16. Leconte M, Chapron C, Dousset B,. Surgical treatment of rectal endometriosis. J Chir (Paris). 2007; 144 (1): 5-10.
17. Rogers PA, D'Hooghe TM, Fazleabas A,. Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci. 2009; 16 (4): 335-346.
18. Ngo C, Chereau C, Nicco C, Weill B, Chapron C, Batteux F,. Reactive oxygen species controls endometriosis progression. Am J Pathol. 2009; 175 (1): 225-234.
19. Ngo C, Nicco C, Leconte M,. Protein kinase inhibitors can control the progression of endometriosis in vitro and in vivo. J Pathol. 2010; 222 (2): 148-157.
20. Li MQ, Shao J, Meng YH,. NME1 suppression promotes growth, adhesion and implantation of endometrial stromal cells via Akt and MAPK/Erk1/2 signal pathways in the endometriotic milieu. Hum Reprod. 2013; 28 (10): 2822-2831.
21. Leconte M, Nicco C, Ngo C,. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol. 2011; 179 (2): 880-889.
22. Kim TH, Yu Y, Luo L, Lydon JP, Jeong JW, Kim JJ,. Activated AKT pathway promotes establishment of endometriosis. Endocrinology. 2014; 155 (5): 1921-1930.
23. Santulli P, Chouzenoux S, Fiorese M,. Protein oxidative stress markers in peritoneal fluids of women with deep infiltrating endometriosis are increased. Hum Reprod. 2015; 30 (1): 49-60.
24. Sebolt-Leopold JS, Herrera R,. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004; 4 (12): 937-947.
25. Streuli I, de Ziegler D, Santulli P,. An update on the pharmacological management of endometriosis. Expert Opin Pharmacother. 2013; 14 (3): 291-305.
26. Wilhelm SM, Carter C, Tang L,. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64 (19): 7099-7109.
27. Coriat R, Nicco C, Chereau C,. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther. 2012; 11 (10): 2284-2293.
28. Chapron C, Lafay-Pillet MC, Monceau E,. Questioning patients about their adolescent history can identify markers associated with deep infiltrating endometriosis. Fertil Steril. 2011; 95 (3): 877-881.
29. Chapron C, Souza C, de Ziegler D,. Smoking habits of 411 women with histologically proven endometriosis and 567 unaffected women. Fertil Steril. 2010; 94 (6): 2353-2355.
30. Revised American Fertility Society classification of endometriosis: 1985. Fertil Steril. 1985; 43 (3): 351-352.
31. Noyes RW, Hertig AT, Rock J,. Dating the endometrial biopsy. Am J Obstet Gynecol. 1975; 122 (2): 262-263.
32. Chapron C, Bourret A, Chopin N,. Surgery for bladder endometriosis: long-term results and concomitant management of associated posterior deep lesions. Hum Reprod. 2010; 25 (4): 884-889.
33. Thubert T, Santulli P, Marcellin L,. Measurement of hs-CRP is irrelevant to diagnose and stage endometriosis: prospective study of 834 patients. Am J Obstet Gynecol. 2014; 210 (6): 533. e531-533. e510.
34. Kavian N, Servettaz A, Marut W,. Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor beta in the skin of mice with scleroderma-like features and prevents the development of the disease. Arthritis Rheum. 2012; 64 (6): 1990-2000.
35. AFS. Revised American Fertility Society classification of endometriosis: 1985. Fertil Steril. 1985; 43 (3): 351-352.
36. Moggio A, Pittatore G, Cassoni P, Marchino GL, Revelli A, Bussolati B,. Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis. Fertil Steril. 2012; 98 (6): 1521-1530. e1522.
37. Ozer H, Boztosun A, Acmaz G, Atilgan R, Akkar OB, Kosar MI,. The efficacy of bevacizumab, sorafenib, and retinoic acid on rat endometriosis model. Reprod Sci. 2013; 20 (1): 26-32.
38. Igney FH, Asadullah K, Zollner TM,. Techniques: species' finest blend - humanized mouse models in inflammatory skin disease research. Trends Pharmacol Sci. 2004; 25 (10): 543-549.
39. Carter CA, Chen C, Brink C,. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol. 2007; 59 (2): 183-195.
40. Tang TC, Man S, Lee CR, Xu P, Kerbel RS,. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia. 2010; 12 (3): 264-274.
41. Krajewska J, Handkiewicz-Junak D, Jarzab B,. Sorafenib for the treatment of thyroid cancer: an updated review. Expert Opin Pharmacother. 2015; 16 (4): 573-583.
42. Kim S, Yazici YD, Calzada G,. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther. 2007; 6 (6): 1785-1792.
43. McLaren J,. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update. 2000; 6 (1): 45-55.
44. McLaren J, Prentice A, Charnock-Jones DS,. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest. 1996; 98 (2): 482-489.
45. McLaren J, Prentice A, Charnock-Jones DS, Smith SK,. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod. 1996; 11 (1): 220-223.
46. Nap AW, Griffioen AW, Dunselman GA,. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab. 2004; 89 (3): 1089-1095.
47. Vodolazkaia A, El-Aalamat Y, Popovic D,. Evaluation of a panel of 28 biomarkers for the non-invasive diagnosis of endometriosis. Hum Reprod. 2012; 27 (9): 2698-2711.
48. Santulli P, Chouzenoux S, Fiorese M,. Protein oxidative stress markers in peritoneal fluids of women with deep infiltrating endometriosis are increased. Hum Reprod. 2015; 30 (1): 49-60.
49. Becker CM, Rohwer N, Funakoshi T,. 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol. 2008; 172 (2): 534-544.
50. Xu M, Zheng YL, Xie XY,. Sorafenib blocks the HIF-1alpha/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells. DNA Cell Biol. 2014; 33 (5): 275-281.